The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Sulforaphane in Patients With Prodromal to Mild Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04213391
Recruitment Status : Unknown
Verified May 2019 by Second Affiliated Hospital, School of Medicine, Zhejiang University.
Recruitment status was:  Recruiting
First Posted : December 30, 2019
Last Update Posted : May 12, 2020
Sponsor:
Information provided by (Responsible Party):
Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
In this proposed study, the investigators will evaluate the efficacy, safety and related mechanism of sulforaphane in treatment of Alzheimer's disease (AD). The study will recruit 160 AD patients, and then these patients will be randomized to sulforaphane group or placebo group (80 patients per arm) for 24 weeks clinic trial. Clinical efficacy and safety assessment will be done at screen/baseline, 4 week, 12 week, and 24 week. The specific aims are to compare sulforaphane versus placebo on: clinical core symptoms; biological samples also will be collected, and stored to research related mechanisms. During the study period, safety index including blood and urine routine, liver and kidney function, coagulation index and clinical effect index about neuropsychological scales will be recorded.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Dietary Supplement: sulforaphane Dietary Supplement: Placebo Not Applicable

Detailed Description:
In this proposed study, the investigators will evaluate the efficacy, safety and related mechanism of sulforaphane in treatment of AD. The study will recruit 160 AD patients, then these patients will be randomized to sulforaphane group or placebo group (80 patients per arm) for 24 weeks clinic trial. Clinical efficacy and safety assessment will be done at screen/baseline, 4 week, 12 week, 24 week. The specific aims are to compare sulforaphane versus placebo on: 1) clinical core symptoms; The investigators hypothesize that (1) sulforaphane is superior to placebo in the treatment of clinical symptoms in patients with AD, measured by the ADAS-cog, MMSE Scale, Moca; (2) Biological samples will be collected, and stored so that the hypothesis sulforaphane may alter oxidative stress indexes or inflammatory biomarkers, and influence histone deacetylase inhibitor mechanism or inflammatory mechanism et al that may be significantly correlated with clinical improvement. (3) Safety index including blood and urine routine, liver and kidney function, coagulation index and clinical effect index about neuropsychological scales will be recorded.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized,Double-blind, Placebo-controlled, Efficacy and Safety Study of Sulforaphane in Patients With Prodromal to Mild Alzheimer's Disease
Estimated Study Start Date : May 10, 2020
Estimated Primary Completion Date : November 1, 2022
Estimated Study Completion Date : December 1, 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: sulforaphane group
The patients will take sulforaphane for 24 weeks, 2550mg once a day.
 Dietary Supplement: sulforaphane
Sulforaphane take 2550mg once a day.
Placebo Comparator: Placebo group
The patients will take placebo for 24 weeks, 2550mg once a day.
 Dietary Supplement: Placebo
Placebo take 2550mg once a day.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The Alzheimer's Disease Assessment Scale [ Time Frame: From baseline to 24 weeks ]
    The Alzheimer's Disease Assessment Scale (ADAS-cog) will be performed to test the cognition of patients at the enrollment, week 12 and week 24. The score ranges from 0 to 75，and higher values represent a better outcome.


Secondary Outcome Measures :
  1. Alzheimer's Disease Collaborative research group-Activities of Daily Living scores. [ Time Frame: From baseline to 24 weeks ]
    Alzheimer's Disease Collaborative research group-Activities of Daily Living scores (ADCS-ADL) will be performed to test the activities of patients at the enrollment,week 6 and week12.The score ranges from 0 to 54，and higher values represent a better outcome.

  2. Neuropsychiatric Inventory scores [ Time Frame: baseline time to 24 weeks ]
    Neuropsychiatric Inventory scores (NPI) will be performed to test the mental symptoms of patients at the enrollment and week12.The score ranges from 0 to 144，and higher values represent a worse outcome.

  3. Mini-Mental State Examination scores [ Time Frame: baseline time to 24 weeks ]
    Mini-Mental State Examination scores(MMSE) will be performed to test the cognition of patients at the enrollment and week12.The score ranges from 0 to 30，and higher values represent a better outcome.

  4. Montreal Cognitive Assessment scores [ Time Frame: baseline time to 24 weeks ]
    Montreal Cognitive Assessment scores (MoCA) will be performed to test the cognition of patients at the enrollment and week12.The score ranges from 0 to 30，and higher values represent a better outcome.

  5. Clinician Interview-Based Impression of Change plus caregiver input [ Time Frame: baseline time to 24 weeks ]
    Clinician Interview-Based Impression of Change plus caregiver input (CIBIC-plus) is widely used in antidementia drug trials. It comprises Likert scales for disease severity and changes, and written accounts summarizing semistructured interviews evaluating behavior, cognition, and function.


Other Outcome Measures:
  1. Oxidative stress indexes [ Time Frame: At baseline and 24 week/endpoint ]
    The change of Oxidative stress indexes as tested by Oxidative stress indexes detection kit

  2. Epigenetics indicators [ Time Frame: At baseline and 24 week/endpoint ]
    The change of Epigenetics indicators as tested by Epigenetics indicators

  3. Cytokines & Chemokines [ Time Frame: At baseline and 24 week/endpoint ]
    The change of Cytokines & Chemokines as tested by Cytokines & Chemokines detection kit

  4. Metabolites [ Time Frame: At baseline and 24 week/endpoint ]
    The change of Metabolites as tested by Metabolites detection kit

  5. RNA expression [ Time Frame: At baseline and 24 week/endpoint ]
    The change of RNA expression as tested by RNA expression detection kit

  6. Intestinal microflora [ Time Frame: At baseline and 24 week/endpoint ]
    The change of intestinal microflora as tested by Metagenomic technique


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Age range from 50 to 75 (including 50 and 75 years old), regardless of ethnic group or gender;
  • 2. The subjects should be able to complete the cognitive ability measurement and other tests specified in the protocol;
  • 3. Meeting the criteria for likely Alzheimer's Disease （AD） dementia (2011) by National Institute of Neurological Disorders and Strokes - Alzheimer's Disease and Related Diseases Association（NINCDS-ADRDA）;
  • 4. Patients with mild dementia: the total score of Mini-Mental State Examination (MMSE) : ≥22 points; Clinical Dementia Rating scale （CDR）score > or equal to 0.5 and < or equal to1；The MMSE score provides evidence of mild disease severity and the CDR-GS score indicates that the patients have noticeable amnestic (pAD) or cognitive and functional (mAD) deficits
  • 5. The total score of the Hachinski Ischemic Score （HIS ）was < 4.
  • 6. Hamilton depression scale (17 items) total score ≤7 points;
  • 7. Brain MRI shows a high likelihood of AD;
  • 8. Before enrollment, patients should take a stable dose of dementia drugs (donepezil 5mg) ≥8 weeks;
  • 9. The expected survival time is > 1 year;
  • 10. Subjects should have a stable and reliable caregiver, or at least have frequent contact with the caregiver (at least 3 days per week and at least 2 hours per day), who will help patients participate in the whole study; Caregivers must accompany the subjects to the visit and assist in completing the relevant scale.

Exclusion Criteria:

  • 1. Refuse to sign the inform consent form;
  • 2. Other causes of dementia: known vascular, central nervous system infection ,Parkinson's disease, traumatic brain dementia, other physical and chemical factors; serious body disease , intracranial space-occupying lesions, endocrine system disease, such as thyroid disease, and a lack of vitamin B12, folic acid, or any other known causes of dementia.
  • 3. Central nervous system diseases (including stroke, optic neuromyelitis, Parkinson's disease, epilepsy, etc.);
  • 4. Obvious positive signs of nervous system examination;
  • 5. Psychotic patients, including schizophrenia or other disorders with bipolar disorder, major depression or delirium;
  • 6. Uncontrolled hypertension or hypotension during screening: systolic blood pressure ≥180（millimetres of mercury ）mmHg or < 90mmhg, or diastolic blood pressure ≥120mmHg or < 60mmhg;
  • 7. Unstable or severe diseases of the heart, lung, liver, kidney and hematopoietic system according to the judgment of the researchers;
  • 8. Patients with incurable visual and auditory disorders that cannot complete neuropsychological tests and scales;
  • 9. Female subjects who are positive in pregnancy test or breast-feeding and who cannot take effective contraceptive measures or have a birth plan;
  • 10. Severe allergy, non-allergic drug reaction or multi-drug allergy history;
  • 11. Participated in other clinical trials within 3 months before screening visit;
  • 12. Taking any health care products related to brain and brain improvement currently and failing to keep the promise to stop using the above products;
  • 13. Other conditions are unsuitable for participating in this study according to the judgement of researchers.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04213391


Contacts
Layout table for location contacts
Contact: Qing-Qing tao, Ph.D +08613777820430 qingqingtao@zju.edu.cn

Locations
Layout table for location information
China, Zhejiang
Second Affiliated Hospital,Zhejiang University School of Medicine Recruiting
Hangzhou, Zhejiang, China, 310009
Contact: Zhi-Ying Wu, MD&PhD    +86-571-87783569    zhiyingwu@zju.edu.cn   
Sponsors and Collaborators
Second Affiliated Hospital, School of Medicine, Zhejiang University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier: NCT04213391    
Other Study ID Numbers: Wulab-AD sulforaphane
First Posted: December 30, 2019    Key Record Dates
Last Update Posted: May 12, 2020
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
 Neurocognitive Disorders
Mental Disorders
Sulforaphane
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents